List view / Grid view

Vasopharm

 

news

Vasopharm enrols first patient in phase III traumatic brain injury trial

8 September 2016 | By Niamh Louise Marriott, Digital Content Producer

Vasopharm's ronopternin (VAS203) will be evaluated for its safety and efficacy as the first patient is enrolled into the nostra phase III (NO Synthase in TRAumatic Brain Injury) trial – a clinical study to assess whether the drug can be used as a initial treatment for moderately to severely injured…